Cargando…
Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors
Metallo-β-lactamases (MβLs) are the target enzymes of β-lactam antibiotic resistance, and there are no effective inhibitors against MβLs available for clinic so far. In this study, thirteen halogen-substituted triazolethioacetamides were designed and synthesized as a potent skeleton of MβLs inhibito...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471427/ https://www.ncbi.nlm.nih.gov/pubmed/30934584 http://dx.doi.org/10.3390/molecules24061174 |
_version_ | 1783412026677133312 |
---|---|
author | Zhang, Yilin Yan, Yong Liang, Lufan Feng, Jie Wang, Xuejun Li, Li Yang, Kewu |
author_facet | Zhang, Yilin Yan, Yong Liang, Lufan Feng, Jie Wang, Xuejun Li, Li Yang, Kewu |
author_sort | Zhang, Yilin |
collection | PubMed |
description | Metallo-β-lactamases (MβLs) are the target enzymes of β-lactam antibiotic resistance, and there are no effective inhibitors against MβLs available for clinic so far. In this study, thirteen halogen-substituted triazolethioacetamides were designed and synthesized as a potent skeleton of MβLs inhibitors. All the compounds displayed inhibitory activity against ImiS with an IC(50) value range of 0.032–15.64 μM except 7. The chlorine substituted compounds (1, 2 and 3) inhibited NDM-1 with an IC(50) value of less than 0.96 μM, and the fluorine substituted 12 and 13 inhibited VIM-2 with IC(50) values of 38.9 and 2.8 μM, respectively. However, none of the triazolethioacetamides exhibited activity against L1 at inhibitor concentrations of up to 1 mM. Enzyme inhibition kinetics revealed that 9 and 13 are mixed inhibitors for ImiS with K(i) values of 0.074 and 0.27μM using imipenem as the substrate. Docking studies showed that 1 and 9, which have the highest inhibitory activity against ImiS, fit the binding site of CphA as a replacement of ImiS via stable interactions between the triazole group bridging ASP120 and hydroxyl group bridging ASN233. |
format | Online Article Text |
id | pubmed-6471427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64714272019-04-26 Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors Zhang, Yilin Yan, Yong Liang, Lufan Feng, Jie Wang, Xuejun Li, Li Yang, Kewu Molecules Communication Metallo-β-lactamases (MβLs) are the target enzymes of β-lactam antibiotic resistance, and there are no effective inhibitors against MβLs available for clinic so far. In this study, thirteen halogen-substituted triazolethioacetamides were designed and synthesized as a potent skeleton of MβLs inhibitors. All the compounds displayed inhibitory activity against ImiS with an IC(50) value range of 0.032–15.64 μM except 7. The chlorine substituted compounds (1, 2 and 3) inhibited NDM-1 with an IC(50) value of less than 0.96 μM, and the fluorine substituted 12 and 13 inhibited VIM-2 with IC(50) values of 38.9 and 2.8 μM, respectively. However, none of the triazolethioacetamides exhibited activity against L1 at inhibitor concentrations of up to 1 mM. Enzyme inhibition kinetics revealed that 9 and 13 are mixed inhibitors for ImiS with K(i) values of 0.074 and 0.27μM using imipenem as the substrate. Docking studies showed that 1 and 9, which have the highest inhibitory activity against ImiS, fit the binding site of CphA as a replacement of ImiS via stable interactions between the triazole group bridging ASP120 and hydroxyl group bridging ASN233. MDPI 2019-03-25 /pmc/articles/PMC6471427/ /pubmed/30934584 http://dx.doi.org/10.3390/molecules24061174 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Zhang, Yilin Yan, Yong Liang, Lufan Feng, Jie Wang, Xuejun Li, Li Yang, Kewu Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors |
title | Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors |
title_full | Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors |
title_fullStr | Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors |
title_full_unstemmed | Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors |
title_short | Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors |
title_sort | halogen-substituted triazolethioacetamides as a potent skeleton for the development of metallo-β-lactamase inhibitors |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471427/ https://www.ncbi.nlm.nih.gov/pubmed/30934584 http://dx.doi.org/10.3390/molecules24061174 |
work_keys_str_mv | AT zhangyilin halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors AT yanyong halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors AT lianglufan halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors AT fengjie halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors AT wangxuejun halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors AT lili halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors AT yangkewu halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors |